Drug Profile
TP 10 - Tillotts Pharma
Alternative Names: TP-10 - Tillotts PharmaLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Tillotts Pharma
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Switzerland
- 22 Mar 2018 Tillotts Pharma licenses Cell Line Technology from BioWa and Lonza for the development of TP 10
- 22 Jan 2018 Tillotts Pharma in-licenses certain rights for the antibody technology developed at the University of Oslo and Oslo University Hospital